GlobVAC - Vaccine production in chloroplasts against Dengue fever
Abstract
Dengue is an important mosquito-borne viral disease that is re-emerging in many parts of the world (Swaminathan and Khanna 2009). In the absence of an effective dengue vaccine and antiviral drug, an integrated vector control program, incorporating source reduction, law enforcement and public education, has been the method of choice for controlling dengue. With increased globalization and climate change, prevention and control of dengue have become even more challenging. Thus, the project contributes scientifically to three major aspects: 1) development of a new vaccine against dengue; 2) a cost-effective and safe vaccine production system via tobacco chloroplast engineering (described in detail below); 3) vaccine research on a disease threatening billions worldwide, especially children, and still increasing and 4) an Indo-Austrian-Norwegian joint initiative to exploit the expertise of partners from these countries aiming at a long term collaboration. The project is funded by the Norwegian Global Health and Vaccination Research (GLOBVAC) Program.
keywords Dengue fever Vaccines Chloroplasts Plastids
Publikationen
Chloroplast-Based Expression of Recombinant Proteins by Gateway® Cloning Technology
Autoren: Gottschamel, J; Lössl, A Jahr: 2016
Chapter in collected volumes
Project staff
Hans-Peter Kaul
Univ.Prof. Dipl.-Ing. Dr.nat.techn. Hans-Peter Kaul
hans-peter.kaul@boku.ac.at
Tel: +43 1 47654-95111
BOKU Project Leader
01.05.2010 - 30.06.2014
BOKU partners
External partners
Bioforsk Norway
Dr. Jihong Clarke
partner
ICGEB, New Delhi
S. Swaminathan
partner